Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.
To aid in prioritizing the development of tuberculosis (TB) vaccines most likely to reach the 2050 TB elimination goal, we estimated the impact and cost-effectiveness of a range of vaccine profiles in low- and middle-income countries.
WHO goals and milestones
Project details
Country
China, Colombia, Congo, Congo D.R.C., Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Ethiopia, Fiji, Gabon, Gambia, Georgia, Ghana, Guinea, Guinea-Bissau, Guyana, Honduras, India, Indonesia, Jamaica, Kazakhstan, Kenya, Kyrgyzstan, Lebanon, Lesotho, Liberia, Madagascar, Malawi, Malaysia, Mali, Mauritania, Mexico, Morocco, Mozambique, Myanmar, Namibia, Nepal, Nicaragua, Niger, Nigeria, Pakistan, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Romania, Russia, Rwanda, Senegal, Serbia, Sierra Leone, Somalia, South Africa, Sri Lanka, Sudan, Swaziland, Tajikistan, Tanzania, Thailand, Togo, Tunesia, Türkiye, Uganda, Ukraine, Uruguay, Uzbekistan, Vietnam, Zambia, Zimbabwe
